Clinical trials: Sexually Transmitted Infection (STI)
Genital Warts
Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts
The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.
- Trial name
- NCT00499967
- Testing
- GS-9191 ointment, GS-9191
- Where
- 25 sites in United States
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
HIV Infections
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with…
- Trial name
- NCT00035932
- Testing
- Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
- Where
- 29 sites in United States
- Volunteers
- 571 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
The Safety and Effectiveness of 935U83 in HIV-Infected Patients
To assess the safety, tolerance, and steady-state pharmacokinetics of multiple oral doses of 935U83 administered to patients with HIV infection. To obtain preliminary evidence of antiretroviral activity of 935U83.
- Trial name
- NCT00002338
- Testing
- Raluridine
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Glaxo Wellcome
Human Immunodeficiency Virus
Kaletra in Combination With Antiretroviral Agents
The purpose of this study is to investigate the tolerability of Kaletra (lopinavir/ritonavir) in combination with new substances such as integrase inhibitors (INIs), C-C chemokine receptor type 5 (CCR5) antagonists, and new…
- Trial name
- PROTEKT (NCT01076179)
- Volunteers
- 502 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00578227
- Testing
- Cervarix™, Twinrix ™ Paediatric
- Where
- 21 sites in Canada, Denmark and 2 more
- Volunteers
- 814 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus
A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the active moiety of BMS-663068), there is no…
- Trial name
- NCT02480894
- Testing
- BMS-663068, Maraviroc
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection
Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects
The purpose of this study was to examine the safety, efficacy, and pharmacokinetics of different dosages of deferiprone in subjects with or without HIV infection.
- Trial name
- NCT02191657
- Testing
- Deferiprone
- Where
- South Africa
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Mycoses, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult…
- Trial name
- NCT00002277
- Testing
- Fluconazole, Amphotericin B
- Where
- 3 sites in United States
- Sponsor
- Pfizer
HIV Infections, HIV Seronegativity
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV.
- Trial name
- NCT00002441
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- Where
- 67 sites in United States, Canada and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- VaxGen
HIV Infections
A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines
The purpose of this study is to see if it is safe and effective to give AIDSVAX B/B or AIDSVAX B/E, two potential HIV vaccines, to HIV-negative volunteers.
- Trial name
- NCT00002402
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, Aluminum hydroxide
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VaxGen
Health Risk Behaviors
Sexually Active Adolescent Focused Education
SAAFE will be pilot tested in 2 geographically distinct areas (Washington, DC and Deep South) with 100 participants from each site to 1) primarily assess the efficacy of improved self-efficacy, knowledge about HIV/STIs and…
- Trial name
- SAAFE (NCT03646032)
- Testing
- SAAFE, Control
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Benten Technologies, Inc.
HIV Infections
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
The primary objective of this study is to determine the preliminary efficacy and tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic HIV+ patients with 200 to 500 CD4+…
- Trial name
- NCT00001993
- Testing
- Butyldeoxynojirimycin, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- G D Searle
Cytomegalovirus Retinitis, HIV Infections
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
- Trial name
- NCT00002187
- Testing
- Fomivirsen sodium
- Where
- 17 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Sarcoma, Kaposi, HIV Infections
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered…
- Trial name
- NCT00002093
- Testing
- Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate
- Where
- 13 sites in United States
- Sponsor
- Nexstar Pharmaceuticals
HPV Infection
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1.
- Trial name
- 9vHPV-BCG (NCT06959563)
- Testing
- 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study of Viracept in HIV-Positive Women
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3.
- Trial name
- NCT00002171
- Testing
- Nelfinavir mesylate
- Where
- 4 sites in United States
- Sponsor
- Agouron Pharmaceuticals
Anogenital Warts
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
An exploratory open label, single treatment trial of anogenital warts with Picato® repeated up to 2 times with two weeks intervals.
- Trial name
- NCT02377999
- Testing
- Picato
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Genital Warts
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative…
- Trial name
- NCT00189293
- Testing
- Imiquimod, vehicle cream
- Where
- 12 sites in Italy
- Volunteers
- 128 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.